This dataset describes a randomized clinical trial (Goldman et al., 1996) in which both survival and longitudinal data were collected to compare the efficacy and safety of two antiretroviral drugs, namely ddI (didanosine) and ddC (zalcitabine), in treating HIV-infected patients intolerant or failing zidovudine (AZT) therapy.
data.frame in the unbalanced format with 1405 longitudinal
observations from 467 subjects. The columns are:
integer: number for patient identification.
numeric: time to death (or censoring).
integer: event indicator. Coded as
1 = death.
numeric: measurement times for the repeated CD4 count measurements.
numeric: CD4 cell counts measured at
factor: drug indicator. Coded as
ddI = didanosine
ddC = zalcitabine.
factor: gender indicator. Coded as
factor: opportunistic infection indicator. Coded as
AIDS = AIDS diagnosis at study entry, and
noAIDS = no
factor: AZT intolerance/failure indicator. Coded as
Guo X, Carlin B. Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician. 2004; 58: 16<e2><80><93>24.
Goldman A, Carlin B, Crane L, Launer C, Korvick J, Deyton L, Abrams K. Response of CD4+ and clinical consequences to treatment using ddI or ddC in patients with advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996; 11: 161<e2><80><93>169. URL: http://www.biostat.umn.edu/~brad/data.html.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.